NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model

Reuters

2025/07/25

NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model

NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta $(OI)$ in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498701-en) on July 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554738528"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554738528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554738528?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554738528","market":"nz","top_or_hot":-1,"title":"NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta <a href=\"https://laohu8.com/S/OI\">$(OI)$</a> in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498701-en) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-25 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta <a href=\"https://laohu8.com/S/OI\">$(OI)$</a> in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498701-en) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDLsCY0L:1","article_id":"2554738528","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554738528","pubTimestamp":1753387536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta  in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","NXTC":"Nextcure Inc.","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技"},"translate_title":"NextCure Inc.宣布抗Siglec-15治疗NC605在成骨不全模型中的有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXTC":0.9,"NDAQ":0.9},"content_text":"NextCure Inc. Announces Promising Preclinical Results for Anti-Siglec-15 Treatment NC605 in Osteogenesis Imperfecta Model\n    \n\n        NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta $(OI)$ in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498701-en) on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}